{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:18:40Z","timestamp":1778285920145,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.neuropharm.2020.108376","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T12:26:25Z","timestamp":1603715185000},"page":"108376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Neuropharmacological and antidepressant-like effects of ZY-1408: A novel serotonin\/norepinephrine reuptake inhibitor and serotonin receptor 2C antagonist"],"prefix":"10.1016","volume":"182","author":[{"given":"Nana","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murezati","family":"Tiliwaerde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zengliang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108376_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/bmb\/57.1.161","article-title":"Meta-analytical studies on new antidepressants","volume":"57","author":"Anderson","year":"2001","journal-title":"Br. Med. Bull."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108376_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00213-005-0087-3","article-title":"Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties","volume":"182","author":"Artaiz","year":"2005","journal-title":"Psychopharmacology (Berlin)"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108376_bib3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/appi.ajp.2009.09020186","article-title":"Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study","volume":"167","author":"Blier","year":"2010","journal-title":"Am. J. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108376_bib4","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/BF00181937","article-title":"The effects of chronic antidepressant treatment in an animal model of anxiety","volume":"95","author":"Bodnoff","year":"1988","journal-title":"Psychopharmacology (Berlin)"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108376_bib5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.npp.1301410","article-title":"Chronic unpredictable stress induces a cognitive deficit and anxiety-like behavior in rats that is prevented by chronic antidepressant drug treatment","volume":"33","author":"Bondi","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108376_bib6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2020.108376_bib7","article-title":"Antidepressant-like activity of YL-0919: a novel combined selective serotonin reuptake inhibitor and 5-HT1A receptor agonist","volume":"8","author":"Chen","year":"2013","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.neuropharm.2020.108376_bib8","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s11064-010-0245-9","article-title":"Na+, K+ ATPase activity is reduced in amygdala of rats with chronic stress-induced anxiety-like behavior","volume":"35","author":"Crema","year":"2010","journal-title":"Neurochem. Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108376_bib9","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","article-title":"Assessing antidepressant activity in rodents: recent developments and future needs","volume":"23","author":"Cryan","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"issue":"14","key":"10.1016\/j.neuropharm.2020.108376_bib10","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: new guidance for publication in BJP","volume":"172","author":"Curtis","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.neuropharm.2020.108376_bib11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4088\/JCP.v62n1106","article-title":"Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo","volume":"62","author":"Entsuah","year":"2001","journal-title":"J. Clin. Psychiatr."},{"issue":"9","key":"10.1016\/j.neuropharm.2020.108376_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/da.20334","article-title":"Anxiety symptoms in Chinese and German adolescents: their relationship with early learning experiences, perfectionism, and learning motivation","volume":"25","author":"Essau","year":"2008","journal-title":"Depress. Anxiety"},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108376_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.jcp.0000132448.65972.d9","article-title":"Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine","volume":"24","author":"Goldstein","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108376_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/sj.mp.4001067","article-title":"Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors","volume":"7","author":"Gonzalez-Maeso","year":"2002","journal-title":"Mol. Psychiatr."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2020.108376_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2012.03.043","article-title":"The N-terminal region of the human 5-HT(2)C receptor has as a cleavable signal peptide","volume":"684","author":"Jahnsen","year":"2012","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108376_bib16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euroneuro.2015.01.005","article-title":"The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor","volume":"25","author":"Jin","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108376_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0149-7634(81)90005-1","article-title":"Acute and chronic stress effects on open field activity in the rat: implications for a model of depression","volume":"5","author":"Katz","year":"1981","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108376_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0149-7634(81)90007-5","article-title":"Amphetamine and tranylcypromine in an animal model of depression: pharmacological specificity of the reversal effect","volume":"5","author":"Katz","year":"1981","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108376_bib19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0028-3908(03)00268-5","article-title":"Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats","volume":"45","author":"Koch","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108376_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neuropharm.2019.05.026","article-title":"Neurotensin receptors inhibit mGluR I responses in nigral dopaminergic neurons via a process that undergoes functional desensitization by G-protein coupled receptor kinases","volume":"155","author":"Martini","year":"2019","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108376_bib21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2005.11.006","article-title":"Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application","volume":"110","author":"Millan","year":"2006","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108376_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrd3628","article-title":"Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy","volume":"11","author":"Millan","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108376_bib23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0022-3565(24)29415-5","article-title":"S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine","volume":"298","author":"Millan","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108376_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbr.2006.07.029","article-title":"Effects of unpredictable chronic mild stress on anxiety and depression-like behavior in mice","volume":"175","author":"Mineur","year":"2006","journal-title":"Behav. Brain Res."},{"issue":"21","key":"10.1016\/j.neuropharm.2020.108376_bib25","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108376_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1254\/jphs.FPJ05010X","article-title":"Detailed pharmacological characterization of 5-HT1A-receptor-mediated [35S]GTP gamma S binding in rat hippocampal membranes","volume":"98","author":"Odagaki","year":"2005","journal-title":"J. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108376_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0091-3057(93)90310-P","article-title":"MK-801 and enantiomers: potential antidepressants or false positives in classical screening models?","volume":"46","author":"Panconi","year":"1993","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2020.108376_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-2999(96)00675-9","article-title":"Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression","volume":"316","author":"Papp","year":"1996","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108376_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0165-0270(80)90021-7","article-title":"AChE-stained horizontal sections of the rat brain in stereotaxic coordinates","volume":"3","author":"Paxinos","year":"1980","journal-title":"J. Neurosci. Methods"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108376_bib30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/aps.2017.83","article-title":"YL-0919, a dual 5-HT1A partial agonist and SSRI, produces antidepressant- and anxiolytic-like effects in rats subjected to chronic unpredictable stress","volume":"39","author":"Ran","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2020.108376_bib31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.brainres.2005.12.052","article-title":"Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503","volume":"1073\u20131074","author":"Rosenzweig-Lipson","year":"2006","journal-title":"Brain Res."},{"issue":"5634","key":"10.1016\/j.neuropharm.2020.108376_bib32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.1083328","article-title":"Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants","volume":"301","author":"Santarelli","year":"2003","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.neuropharm.2020.108376_bib33","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","article-title":"SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants","volume":"10","author":"Stahl","year":"2005","journal-title":"CNS Spectr."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108376_bib34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuropharm.2020.108376_bib35","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuint.2016.03.013","article-title":"A kinome wide screen identifies novel kinases involved in regulation of monoamine transporter function","volume":"98","author":"Vuorenpaa","year":"2016","journal-title":"Neurochem. Int."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108376_bib36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/BF00187257","article-title":"Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant","volume":"93","author":"Willner","year":"1987","journal-title":"Psychopharmacology (Berlin)"},{"issue":"7","key":"10.1016\/j.neuropharm.2020.108376_bib37","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.euroneuro.2012.06.001","article-title":"Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor","volume":"23","author":"Xue","year":"2013","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"9","key":"10.1016\/j.neuropharm.2020.108376_bib38","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/bph.13675","article-title":"Neurochemical and behavioural effects of hypidone hydrochloride (YL-0919): a novel combined selective 5-HT reuptake inhibitor and partial 5-HT1A agonist","volume":"174","author":"Zhang","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"Pt A","key":"10.1016\/j.neuropharm.2020.108376_bib39","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.neuropharm.2016.11.004","article-title":"Antidepressant-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in chronically stressed rats","volume":"113","author":"Zhang","year":"2017","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:06:26Z","timestamp":1758438386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820304445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":39,"alternative-id":["S0028390820304445"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108376","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuropharmacological and antidepressant-like effects of ZY-1408: A novel serotonin\/norepinephrine reuptake inhibitor and serotonin receptor 2C antagonist","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108376"}}